Boehringer Ingelheim Venture Fund (BIVF)

https://www.boehringer-ingelheim-venture.com

Created in 2010, the Boehringer Ingelheim Venture Fund (BIVF) invests in ground-breaking therapeutics-focused biotechnology companies to drive innovation in biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF’s focus is to target unprecedented therapeutic concepts addressing high medical needs in immuno-oncology, regenerative medicine, infectious diseases, and digital health. These may include novel platform technologies to address so far undruggable targets, new generation vaccines and/or new biological entities. BIVF takes an active role with its portfolio companies – delivering significant added value through its own extensive drug discovery, scientific and managerial expertise. BIVF has a fund volume of 300 million euros and currently supervises a portfolio of more than 40 companies. *

	Start	2010-03-01 established
	Group	Boehringer Ingelheim (Group)
	Industry	venture capital
	Industry 2	pharmaceutical
	Person	Kalkbrenner, Frank (Boehringer 201308 CVP + Head of BIVF + CEO Acousia Therapeutics GmbH)

	Region	Ingelheim
	Country	Germany
	Street	173 Binger Str.
	City	55216 Ingelheim
	Tel	+49-6132-77-8740
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	300,000,000 (capital under management (2022) 2022-03-03)

		* Document for »About Section«: ArrePath. (3/3/22). "Press Release: ArrePath Announces $20 Million Seed Financing to Advance its Machine Learning-based Platform for Discovery of Novel Anti-infectives Addressing Antimicrobial Resistance". Princeton, NJ.

		Record changed: 2024-10-29